The efficacy of pharmacotherapy for decreasing the expansion rate of abdominal aortic aneurysms: a systematic review and meta-analysis.
The efficacy of pharmacotherapy for decreasing the expansion rate of abdominal aortic aneurysms: a systematic review and meta-analysis.
复制标题
药物疗法降低腹主动脉瘤的膨胀率的功效：系统评价和荟萃分析。
DOI：
10.1371/journal.pone.0001895
复制
发表时间：
2008-03-26
期刊：
影响因子：
3.7
通讯作者：
Ghali, William A.
中科院分区：
文献类型：
--
作者：
Guessous, Idris;Periard, Daniel;Lorenzetti, Diane;Cornuz, Jacques;Ghali, William A.
药物治疗可能是限制腹主动脉瘤（AAA）扩张速度的潜在方法。已经进行了评估不同药物减缓人类 AAA 扩张速度的功效的研究，但从未对其进行系统评价或总结。两位独立评审员确定了研究并选择了随机试验和前瞻性队列研究，比较接受药物治疗与未接受药物治疗的患者的 AAA 增长率。我们提取了有关研究干预、基线特征、方法学质量和 AAA 增长率差异（以毫米/年为单位）的信息。十四项前瞻性研究符合资格标准。五项队列研究提出了β受体阻滞剂获益的可能性[汇总增长率差异：-0.62毫米/年，（95%CI，-1.00至-0.24）]，但这在三项β受体阻滞剂RCT中并未得到证实[汇总RCT增长率差异：-0.05毫米/年（-0.16至0.05）]。他汀类药物已在两项队列研究中进行了评估，得出的汇总增长率差异为-2.97（-5.83至-0.11）。强力霉素和罗红霉素已在两项随机对照试验中进行了评估，表明可能具有益处[汇总随机对照试验增长率差异：-1.32 毫米/年（-2.89 至 0.25）]。与此同时，评估非甾体抗炎药、利尿剂、钙通道阻滞剂和血管紧张素转化酶抑制剂的研究没有发现统计学上的显着差异。 β-受体阻滞剂似乎不会显着降低 AAA 的生长速度。他汀类药物和其他抗炎药物似乎有望降低 AAA 的扩张率，但在提出明确建议之前需要进一步评估。
Pharmacotherapy may represent a potential means to limit the expansion rate of abdominal aortic aneurysms (AAAs). Studies evaluating the efficacy of different pharmacological agents to slow down human AAA-expansion rates have been performed, but they have never been systematically reviewed or summarized. Two independent reviewers identified studies and selected randomized trials and prospective cohort studies comparing the growth rate of AAA in patients with pharmacotherapy vs. no pharmacotherapy. We extracted information on study interventions, baseline characteristics, methodological quality, and AAA growth rate differences (in mm/year). Fourteen prospective studies met eligibility criteria. Five cohort studies raised the possibility of benefit of beta-blockers [pooled growth rate difference: −0.62 mm/year, (95%CI, −1.00 to −0.24)], but this was not confirmed in three beta-blocker RCTs [pooled RCT growth rate difference: −0.05 mm/year (−0.16 to 0.05)]. Statins have been evaluated in two cohort studies that yield a pooled growth rate difference of −2.97 (−5.83 to −0.11). Doxycycline and roxithromycin have been evaluated in two RCTs that suggest possible benefit [pooled RCT growth rate difference: −1.32 mm/year (−2.89 to 0.25)]. Studies assessing NSAIDs, diuretics, calcium channel blockers and ACE inhibitors, meanwhile, did not find statistically significant differences. Beta-blockers do not appear to significantly reduce the growth rate of AAAs. Statins and other anti-inflammatory agents appear to hold promise for decreasing the expansion rate of AAA, but need further evaluation before definitive recommendations can be made.
登录
查看更多内容
影响因子：
2
作者：
Berger, VW
通讯作者：
Berger, VW
DOI：
10.1111/j.1749-6632.1996.tb33298.x
发表时间：
1996-01-01
期刊：
ABDOMINAL AORTIC ANEURYSM: GENETICS, PATHOPHYSIOLOGY, AND MOLECULAR BIOLOGY
影响因子：
--
作者：
Cronenwett, JL
通讯作者：
Cronenwett, JL
DOI：
10.1586/14737167.6.5.555
发表时间：
2006-10-01
影响因子：
2.3
作者：
Guessous, Idris;Cornuz, Jacques
通讯作者：
Cornuz, Jacques
影响因子：
4.3
作者：
Juvonen, JJ;Tuvonen, T;Saikku, P
通讯作者：
Saikku, P
影响因子：
4.3
作者：
Laupacis, A
通讯作者：
Laupacis, A